Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Medicine and Science in Sports and Exercise|July 15, 1998
Activity Counseling Trial (ACT): rationale, design, and methods. Activity Counseling Trial Research GroupS N Blair, W B Applegate, A L Dunn, et al.
Journal of Cardiovascular Risk|November 10, 2001
Brachial flow-mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameterD M Herrington, L Fan, M Drum, et al.
Leukemia|January 1, 1989
Low-dose ara-C therapy for acute myelogenous leukemia in elderly patientsB L Powell, R L Capizzi, H B Muss, et al.
Prostate Cancer and Prostatic Diseases|March 9, 2016
Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomyT M Morgan, S R Hawken, K R Ghani, et al.
Journal of Medicinal Chemistry|June 25, 1993
Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acidsR M Keenan, J Weinstock, J A Finkelstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2022
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyZ R Reichert, T M Morgan, G Li, et al.
Urology|December 13, 2021
Developing a Patient-Centered Model of Prostate Cancer Care: Patient Satisfaction With a Survivorship Program Embedded in Urologic-Oncologic CareD Wittmann, C Varlamos, N Rodriguez-Galano, et al.
Clinical Pharmacology and Therapeutics|November 6, 2015
Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and developmentP Vicini, O Fields, E Lai, et al.
Prostate Cancer and Prostatic Diseases|May 25, 2016
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-upD E Spratt, W C Jackson, A Abugharib, et al.
ESMO Open|September 10, 2024
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingD Triner, R P Graf, R W Madison, et al.
Pageof 9